3D Printed Glioblastomas Helps Evaluate Therapeutic Efficacy
By MedImaging International staff writers Posted on 19 Mar 2020 |
Image: A new imaging technique enables the study of 3D-printed brain tumors (Photo courtesy of RPI)
A new study shows how bioprinting and imaging of glioblastoma cells can be used to generate three dimensional (3D) models of brain tumors.
Developed at the European Molecular Biology Laboratory (Heidelberg, Germany), Northeastern University (Boston, MA, USA), the Rensselaer Polytechnic Institute (RPI; Troy, NY, USA), and other institutions, the integrated platform is designed to generate an in-vitro 3D glioblastoma multiforme (GBM) model with perfused vascular channels, made out of patient-derived tumor cell bio-inks printed together with the blood vessels. The bioprinted blood vessels also provide channels for therapeutics to travel through, such as the chemotherapy drug Temozolomide.
In the body, drug delivery to GBM cells is especially complicated because of the blood-brain barrier (BBB). The 3D model, on the other hand, enables long-term culture and drug delivery and provides a more accurate evaluation of a drug's effectiveness than directly injecting the therapy into the cells. The 3D model also facilitates mesoscopic fluorescence molecular tomography (2GMFMT), a novel imaging method that can noninvasively assess longitudinal fluorescent signals from the therapeutic drugs over the whole in vitro model. The study was published on March 6, 2020, in Science Advances.
“There is a need to understand the biology and the complexity of the glioblastoma. What's known is that glioblastomas are very complex in terms of their makeup, and this can differ from patient to patient,” said corresponding author professor of biomedical engineering Xavier Intes, PhD, of RPI. “We developed a new technology that allows us to go deeper than florescence microscopy. It allows us to see, first, if the cells are growing, and then, if they respond to the drug. That's the unique part of the bioprinting that has been very powerful. It's closer to what would happen in vivo.”
GBM is a highly invasive malignant brain tumor that carries a dismal prognosis, with a median survival of 14 months and less than 10% 5-year survival rate after diagnosis, despite aggressive therapy, including surgery, radiotherapy, and chemotherapy.
Related Links:
European Molecular Biology Laboratory
Northeastern University
Rensselaer Polytechnic Institute
Developed at the European Molecular Biology Laboratory (Heidelberg, Germany), Northeastern University (Boston, MA, USA), the Rensselaer Polytechnic Institute (RPI; Troy, NY, USA), and other institutions, the integrated platform is designed to generate an in-vitro 3D glioblastoma multiforme (GBM) model with perfused vascular channels, made out of patient-derived tumor cell bio-inks printed together with the blood vessels. The bioprinted blood vessels also provide channels for therapeutics to travel through, such as the chemotherapy drug Temozolomide.
In the body, drug delivery to GBM cells is especially complicated because of the blood-brain barrier (BBB). The 3D model, on the other hand, enables long-term culture and drug delivery and provides a more accurate evaluation of a drug's effectiveness than directly injecting the therapy into the cells. The 3D model also facilitates mesoscopic fluorescence molecular tomography (2GMFMT), a novel imaging method that can noninvasively assess longitudinal fluorescent signals from the therapeutic drugs over the whole in vitro model. The study was published on March 6, 2020, in Science Advances.
“There is a need to understand the biology and the complexity of the glioblastoma. What's known is that glioblastomas are very complex in terms of their makeup, and this can differ from patient to patient,” said corresponding author professor of biomedical engineering Xavier Intes, PhD, of RPI. “We developed a new technology that allows us to go deeper than florescence microscopy. It allows us to see, first, if the cells are growing, and then, if they respond to the drug. That's the unique part of the bioprinting that has been very powerful. It's closer to what would happen in vivo.”
GBM is a highly invasive malignant brain tumor that carries a dismal prognosis, with a median survival of 14 months and less than 10% 5-year survival rate after diagnosis, despite aggressive therapy, including surgery, radiotherapy, and chemotherapy.
Related Links:
European Molecular Biology Laboratory
Northeastern University
Rensselaer Polytechnic Institute
Latest General/Advanced Imaging News
- PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
- Artificial Intelligence Evaluates Cardiovascular Risk from CT Scans
- New AI Method Captures Uncertainty in Medical Images
- CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
- Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
- CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
- Minimally Invasive Procedure Could Help Patients Avoid Thyroid Surgery
- Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery
- AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning
- Imaging Technology Provides Ground-Breaking New Approach for Diagnosing and Treating Bowel Cancer
- CT Coronary Calcium Scoring Predicts Heart Attacks and Strokes
- AI Model Detects 90% of Lymphatic Cancer Cases from PET and CT Images
- Breakthrough Technology Revolutionizes Breast Imaging
- State-Of-The-Art System Enhances Accuracy of Image-Guided Diagnostic and Interventional Procedures
- Catheter-Based Device with New Cardiovascular Imaging Approach Offers Unprecedented View of Dangerous Plaques
- AI Model Draws Maps to Accurately Identify Tumors and Diseases in Medical Images